The historical rank and industry rank for Chordate Medical Holding AB's ROE % or its related term are showing as below:
OSTO:CMH'
s ROE % Range Over the Past 10 Years
Min: -224.48 Med: -109.82 Max: -42
Current: -159.75
During the past 10 years, Chordate Medical Holding AB's highest ROE % was -42.00%. The lowest was -224.48%. And the median was -109.82%.
OSTO:CMH's ROE % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 2.41
vs OSTO:CMH: -159.75
Chordate Medical Holding AB (OSTO:CMH) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2025) net income data. The Revenue data used here is four times the quarterly (Jun. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Chordate Medical Holding AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordate Medical Holding AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's ROE % distribution charts can be found below:
* The bar in red indicates where Chordate Medical Holding AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Chordate Medical Holding AB (OSTO:CMH) has a ROE % of -122.49% as of Jun. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's ROE % too high?
Chordate Medical Holding AB's current ROE % is -122.49%. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's ROE % compare to ABT and SYK?
Chordate Medical Holding AB's ROE % of -122.49% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROE % is 2.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.41, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Chordate Medical Holding AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordate Medical Holding AB's current ROE % is -122.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current ROE % of -122.49%. The stock's GF Value™ is kr26.18, compared to a current price of kr0.16 — trading 99.4% below its estimated fair value. The current ROE % is -122.49%. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current ROE % is -122.49% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chordate Medical Holding AB (OSTO:CMH) Overvalued in 2026?
Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued.
The current stock price of kr0.16 is trading 99.4% below its estimated GF Value™ of kr26.18.
Key valuation signals for OSTO:CMH:
ROE %: -122.49%
GF Value™: kr26.18 vs. price of kr0.16 (99.4% below fair value)
No single metric tells the full story. See the OSTO:CMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score
Get the complete analysis for OSTO:CMH
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CMH has been successfully added to your 
